Winton Group’s Anavex Life Sciences AVXL Stock Holding History

Winton Group’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-91,984	Closed	-$291K	–	1545
2019 Q3	$291K	Buy	+91,984	New	+$265K	﹤0.01%	1284

Other funds holding AVXL

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Winton Group's AVXL Position: Q4 2019 in Review

Winton Group sold out of Anavex Life Sciences (AVXL) in Q4 2019, closing a stake of 91,984 shares — an estimated $291K sold.

Winton Group first reported a position in AVXL in Q3 2019 and held it in 1 quarter. The position peaked at $291K in Q3 2019. 67 funds tracked by Wall St. Rank hold AVXL as of Q4 2019.

Winton Group reported no remaining Anavex Life Sciences position as of Q4 2019 after selling out during the quarter.
Winton Group sold 91,984 Anavex Life Sciences shares in Q4 2019, an estimated $291K.
Winton Group first reported a position in Anavex Life Sciences in Q3 2019 and held it in 1 quarter.
Winton Group's Anavex Life Sciences position peaked at $291K in Q3 2019.
67 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2019.

Based on Winton Group's 13F filing for Q4 2019, filed 13 Feb 2020.